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Introduction: Patients with a diagnosis of rheumatoid arthritis (RA) are at increased risk of
infections. Vaccination is a recommended preventive measure. There are no studies evalu-
ating the practice of vaccination in patients with early RA.
Objectives: To evaluate the frequency of vaccination and the orientation (by the doctor) about
vaccines among patients with early RA diagnosis.
Methods: Cross-sectional study including patients from the early RA Brasilia cohort. Demo-
graphic data, disease activity index (Disease Activity Score 28 – DAS28), functional disability
(Health Assessment Questionnaire – HAQ), and data on treatment and vaccination after
diagnosis of RA were analyzed.
Results: Sixty-eight patients were evaluated, 94.1% women, mean age 50.7 ± 13.2 years.
DAS28 was 3.65 ± 1.64, and HAQ was 0.70. Most patients (63%) had vaccination card. Only
ﬁve  patients (7.3%) were briefed by the doctor about the use of vaccines. Patients were vac-
cinated for MMR (8.8%), tetanus (44%), yellow fever (44%), hepatitis B (22%), inﬂuenza (42%),
H1N1 (61.76%), pneumonia (1.4%), meningitis (1.4%), and chickenpox (1.4%). All patients vac-
cinated with live attenuated virus were undergoing immunosuppressive therapy, and were
vaccinated inadvertently, without medical supervision. There was no association between
the use of any vaccine and disease activity, functional disability, years of education, lifestyle,
and comorbidities.
Conclusion: Patients were infrequently briefed by the physician regarding use of vaccines,
with high frequency of inadvertent vaccination with live attenuated component, whileimmunization with killed virus was below the recommended level.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.04.002.
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Vacinac¸ão  em  pacientes  da  Coorte  Brasília  de  artrite  reumatoide  inicial
Palavras chave:
Vacina
Artrite reumatoide inicial
Populac¸ão  brasileira
r  e  s  u  m  o
Introduc¸ão: Os pacientes com diagnóstico de artrite reumatoide (AR) apresentam risco
aumentado de infecc¸ões. A vacinac¸ão é uma medida preventiva recomendada. Não há
estudos avaliando a prática da vacinac¸ão nos pacientes com AR inicial.
Objetivos: Avaliar a frequência de vacinac¸ão e a orientac¸ão (feita pelo médico) sobre vacinas
entre os pacientes com diagnóstico de AR inicial.
Métodos: Estudo transversal incluindo pacientes da coorte Brasília de AR inicial. Foram anal-
isados dados demográﬁcos, índice de atividade da doenc¸a (Disease Activity Score 28 – DAS28),
incapacidade funcional (Health Assessment Questionnaire – HAQ), dados sobre tratamento e
vacinac¸ão  após o diagnóstico da AR.
Resultados: Foram avaliados 68 pacientes, sendo 94,1% mulheres, com idade média de
50,7  ± 13,2 anos. O DAS28 foi de 3,65 ± 1,64, e o HAQ de 0,70. A maioria dos pacientes (63%)
possuía cartão vacinal. Apenas cinco pacientes (7,3%) foram orientados pelo médico sobre
uso  das vacinas. Os pacientes foram vacinados para tríplice viral (8,8%), tétano (44%), febre
amarela (44%), hepatite B (22%), gripe (42%), inﬂuenza H1N1 (61,76%), pneumonia (1,4%),
meningite (1,4%) e varicela (1,4%). Todos os pacientes vacinados com vírus vivo atenuado
estavam em uso de imunossupressores e receberam as vacinas de forma inadvertida, sem
orientac¸ão  médica. Não houve associac¸ão entre o uso de nenhuma vacina e atividade da
doenc¸a, incapacidade funcional, anos de escolaridade, hábitos de vida, comorbidades.
Conclusão: Os pacientes foram pouco orientados pelo médico com relac¸ão ao uso das vaci-
nas, com elevada frequência de vacinac¸ão inadvertida com componente vivo atenuado,
enquanto a imunizac¸ão com vírus mortos ﬁcou aquém do recomendado.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Infections are an important cause of morbidity and mortal-
ity in patients with rheumatoid arthritis (RA).1 It is estimated
that these patients have a two-fold risk of developing infec-
tion when compared to healthy subjects of the same sex and
age. The increased infectious susceptibility is due not only to
the treatment used, but to the disease itself and to associated
comorbidities.2 Infections occur more  frequently in joints,
bones, skin, soft tissues, and respiratory tract,2 being respon-
sible, at least in part, for an increase in mortality in patients
with RA, especially when they occur in the genitourinary and
bronchopulmonary tracts.3–6
Vaccination is the primary preventive measure against
infectious diseases.7 In patients with RA, depending on the
state of immunosuppression, the immunogenicity of the vac-
cination may be reduced, but is still effective.8 There are some
cases of RA reported following the use of the vaccine, espe-
cially against hepatitis B, but there is no evidence of a causal
relationship established. Thus, currently the administration of
most vaccines recommended by the national immunization
schedule can be performed safely with no effect on disease
activity.7–9
The use of vaccines not containing living organisms, such
as those for inﬂuenza (intramuscular), pneumonia, tetanus,
diphtheria, pertussis, Haemophilus inﬂuenzae type B (Hib), hep-
atitis A and B virus, polio (inactivated – IPV), meningitis and
human papilloma virus (HPV), is recommended in patients
with rheumatic diseases, including RA.8,10 Among those, theinﬂuenza and pneumococcal vaccines are the most suitable,
with a higher level of evidence regarding safety and efﬁcacy.
All vaccines should be administered preferably before the start
of treatment with synthetic or biological disease-modifying
antifheumatic drugs (DMARDs), to try to achieve an adequate
immune response.8,11
The attenuated live vaccines should be avoided, whenever
possible, in patients with rheumatic diseases.8 Included in this
group are the following vaccines: MMR (measles, mumps, and
rubella), BCG, inﬂuenza (nasal), chickenpox, shingles, typhoid,
polio (OPV), smallpox and yellow fever. However, one must
make an individualized assessment of patients, considering
the degree of immunosuppression and the risk factors for
acquiring these infections.8,12,13
Despite the recommendations for the use of vaccines in
patients with rheumatic diseases, the frequency of vacci-
nation is suboptimal, reaching a maximum of 20%-35% in
immunosuppressed patients.14 However, few studies have
evaluated the vaccination coverage of RA patients, with most
studies evaluating only inﬂuenza or antipneumococcal vac-
cines.
The only study evaluating vaccination in patients with
early RA showed that the response of pneumonia vaccine was
lower than that seen in the normal population. Moreover, that
study also noted that the addition of inﬂiximab to the therapy
with methotrexate did not affect the response to the vaccine.15The Brazilian Society of Rheumatology has recently issued
recommendations on vaccination in patients with RA.16 How-
ever, no study evaluating the practice of vaccination, in
general, in patients with early RA in Brazil has been published.
 . 2 0 1 4;5 4(5):349–355 351
n
o
p
P
A
p
c
o
d
y
a
c
i
C
(
o
a
d
t
o
v
2
h
w
c
w
t
o
i
d
–
d
i
q
d
r
g
t
v
o
o
R
S
e
R
(
i
p
a
Table 1 – General characteristics of patients diagnosed
with early RA evaluated for vaccination.
Characteristics N (%) or mean ± standard
deviation (n = 68)
Women 64 (94.1%)
Age (years) 50.7 + 13.2
Time since diagnosis (years) 6 + 2.8
Schooling (years) 8.2 + 3
Treatment
Synthetic DMARDs 67 (98.5%)
Biological DMARDs 14 (20.5%)
DAS 28 3.65  + 1.64r e v b r a s r e u m a t o l
Thus, this study aims to evaluate the frequency of vacci-
ation among patients with early RA diagnosis and verify the
rientation regarding the use of vaccines given by doctors to
atients.
atients  and  methods
 cross-sectional study from February 2012 to June 2012, as
art of the Brasilia Cohort of Early Rheumatoid Arthritis, was
arried out.17–20 Data collection was performed at the Clinic
f Rheumatology, Hospital Universitário de Brasília, Universi-
ade de Brasília (HUB/UnB). We  included patients older than 18
ears diagnosed with early RA (less than one year of symptoms
t diagnosis).
Patients participated voluntarily in the study, after clariﬁ-
ation on the content of the research and after signing a free
nformed consent form. The study was approved by the Ethics
ommittee of the Faculty of Medicine, Universidade de Brasília
CEP/FM-028/2007).
All participants were assessed by direct interview in routine
utpatient consultations. The vaccination card, when avail-
ble, was checked by evaluating those vaccines used after the
iagnosis of RA. If these patients did not possess the vaccina-
ion card, they were asked speciﬁcally about each and every
ne of the national immunization schedule recommended
accines for adults and elderly patients: seasonal inﬂuenza,
3-valent pneumococcal – Pn23, MMR,  tetanus-diphteria (Td),
epatitis B, and yellow fever.21 Moreover, they were evaluated
ith respect to the use of other vaccines: measles, meningo-
occal, and human papillomavirus (HPV) vaccines. Patients
ere also asked if they had received some guidance from
he accompanying physician on which vaccines they would
r would not use.
Information about age, time since diagnosis, disease activ-
ty index (Disease Activity Score 28 – DAS28), functional
isability questionnaire (Health Assessment Questionnaire
 HAQ), use of synthetic or biologic DMARDs (medication,
ose), lifestyle (physical activity, current or previous smok-
ng), education, and comorbidities were also obtained through
uestionnaires and medical record reviews. Patients were then
ivided into groups, according to whether or not they had
eceived each of the vaccines listed above.
Descriptive statistical analysis was used to evaluate the
eneral characteristics of the study population. The Student’s
-test or Mann-Whitney test was used to analyze continuous
ariables. Categorical variables were analyzed by chi-squared
r Fisher’s exact test, when appropriate. The signiﬁcance level
f 5% (p < 0.05) was used for all statistical tests.
esults
ixty-eight patients with early RA were evaluated. The gen-
ral characteristics of the patients are shown in Table 1.
egarding the treatment with immunosuppressive drugs, 55
80%) patients were taking methotrexate, 18 (26%) antimalar-
al drugs, 17 (25%) leﬂunomide, 8 (11%) sulfasalazine, 13 (19%)
rednisone, 6 (8.8%) inﬂiximab, 1 (1.4%) etanercept, 2 (2.9%)
dalimumab, 4 (5.8%) rituximab, and 2 (2.9%) abatacept.HAQ 0.70 + 0.6
Vaccination Card 48 (63%)
Of the total group, only ﬁve patients (7.3%) had been
briefed by the doctor about the use of vaccines. Patients
who underwent vaccination without receiving speciﬁc med-
ical recommendation made it on their own, inadvertently,
at the suggestion of the media or of third parties (rela-
tives/neighbours/acquaintances).
After the RA diagnosis, the use of some kind of inactivated
or recombinant vaccine was observed in 57 (84%) patients; and
the use of kind of live attenuated vaccine was observed in 32
(47%) patients. The vaccination was carried out as follows: 6
(8.8%) for MMR  (measles, rubella, and chicken pox), 30 (44%) for
dT, 30 (44%) for yellow fever, 15 (22%) for hepatitis B, 29 (42%)
for inﬂuenza, 42 (61.7%) for H1N1, 4 (5.8%) for pneumonia, 1
(1.4%) for meningitis, and 1 (1.4%) for varicella (1.4%).
Table 2 shows the analysis of the characteristics of the
group that received seasonal inﬂuenza vaccine compared to
the group of patients who did not receive this vaccine. The
same analysis was done for all vaccines under study.
No association among the use of any vaccine and dis-
ease activity, functional disability, physical activity, smoking,
and years of schooling was noted. Similarly, no difference in
frequency of comorbid conditions that could inﬂuence the
indication of the use of some vaccines, such as cancer and
diabetes mellitus, was observed. No patient had chronic lung
disease or ischemic heart disease. The guidance on which vac-
cine patients should or should not use did not result in higher
or lower frequency of using any vaccine. Also in patients
vaccinated against H1N1 inﬂuenza, there was no observed
difference in relation to drug therapy or use of other vaccines.
With regard to age, patients who received hepatitis B and
MMR  vaccines were younger (44 ± 12 versus 53 ± 13, p = 0.03
and 37 ± 9.5 versus 52 ± 13; p = 0.01, respectively). The time
to diagnosis of RA was longer in the group that received Td
(6.8 ± 2.7 versus 5.4 ± 2.7, p = 0.03) and in those who  used H1N1
inﬂuenza vaccine (6,7 ± 2.6 versus 5 ± 2.9, p = 0.01). The group
that received antipneumococcal vaccine presented higher rate
of patients above 60 years (75% versus 22%, p = 0.04).
Patients using double adult-type vaccine also made more
frequent use of MMR  (20% versus 0%, p < 0.005), hepatitis B (47%
versus 26%, p < 0.001) and yellow fever (63% versus 29%, p = 0.01)
vaccines, compared to the group that has not been vaccinated
with Td.No patient receiving hepatitis B vaccine was treated with
leﬂunomide, with a statistically signiﬁcant difference when
compared with patients who did not receive such a vaccine
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Table 2 – Analysis of patients according to inﬂuenza vaccination.
Inﬂuenza
vaccine
(n = 29)
Non-vaccinated
(n  = 39)
p-value
Age 57.9 + 12.8 45.4 + 10.8 <0.001
>60 years-old 15 2 <0.001
Time to diagnosis 6.7 + 2.8 5.5 + 2.7 0.07
DAS 28 3.6 + 1.7 3.6 + 1.6 0.8
HAQ 0.77 + 0.69 0.60 + 0.68 0.3
Vaccine guidance 2 3 1.0
Vaccines
Pneumococcal 4 0 0.029
MMR 3 3 0.6
Yellow Fever 15 15 0.4
Tetanus-diphteria (Td) 20 10 <0.001
H1N1 18 24 0.8
Meningococcal 1 0 0.4
Varicella 1 0 0.4
Prednisone 9 4 0.5
Synthetic DMARDs 28 39 0.4
Methotrexate 25 30 0.5
Leﬂunomide 7 10 0.8
Antimalarials 7 11 0.9
Sulfasalazine 4 4 0.7
Biological DMARDs 4 10 0.3
Inﬂiximab 1 4 0.3
Adalimumab 1 1 1.0
Etanercept 1 0 1.0
Rituximab 2 2 1.0
Abatacept 0 2 0.5
Smoking
Current 5 1 0.07
Prior 8 11 0.8
Physical activity 11 21 0.2
Neoplasia 0 
Diabetes mellitus 4 
(0% versus 32%, p = 0.015). Patients vaccinated against hepatitis
B also used more  frequently MMR  (33% versus 19%, p = 0.01).
All patients vaccinated with live attenuated viruses (MMR,
varicella and yellow fever) were on immunosuppressive ther-
apy. In all these cases, the vaccination occurred without
guidance given by Rheumatology Department physicians.
Discussion
Despite the increased infectious susceptibility of RA patients
and the importance of vaccination, the practice of pas-
sive immunization has been performed improperly in these
patients.10,14 Our study showed that Brasilia cohort patients
received little guidance (7.3%) from the physician as to
whether or not to use vaccines in general, or speciﬁcally in
relation to contraindications of live virus vaccines. Thus, most
of vaccinated patients in our early RA service received the vac-
cine on their own, regardless of medical advice. This ﬁnding
is very important, because the Brasilia cohort is followed-up
at an outpatient rheumatology tertiary care service, where
the recommendations for vaccination in immunosuppressed
patients should be observed.1 1.0
1 0.1
The lack of recommendation by professionals from a ter-
tiary care service makes us wonder about the situation in
relation to the recommendation to be vaccinated in other
primary and secondary care centers in our country, and
emphasizes the importance of greater disclosure and atten-
tion for that matter.
Work done in other countries showed higher frequency of
medical guidance as to vaccination, with proportions ranging
from 45% to 95%.22–25 We observed no inﬂuence of guid-
ance on the use of any vaccine. However, Doe et al. showed
improvement in the rate of inﬂuenza vaccination after guid-
ance optimization from health professionals, an increase of
56% to 72% in four years of observation.22,23
Besides medical guidance, other factors inﬂuence vac-
cination coverage, for instance, vaccination offered at the
hospital, allergy to vaccine components, and previous adverse
reactions.22–27 The length of rheumatologists’ professional
practice may also interfere with the frequency of passive
immunization. Desai et al. showed a higher proportion of
patients vaccinated against pneumonia in the group of
rheumatologists with ≤ 10 years of practice.28 However,
a Brazilian study evaluating vaccination practice by  pedi-
atric rheumatologists in the state of São Paulo showed no
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nﬂuence of time of professional practice.29 In the early arthri-
is outpatient service where this study was conducted, all
heumatologists have ≤10 years of practice.
We found that the use of some vaccines, such as inﬂuenza,
etanus, and hepatitis B, was an important factor for using
ther vaccines. This may have happened thanks to the best
dvice given to these patients about the importance of vacci-
ation in general. Furthermore, in the place of application of a
articular vaccine (as occurs in primary health services) other
accines may have been provided, in accordance with age and
isk of acquiring other infections.
Regarding vaccination against inﬂuenza, we showed that
accination coverage (42%) was suboptimal, similar to that
eported in other studies for RA.14,22,23 In Brazil, these patients
re the target of the National Campaign for Elderly Vaccina-
ion, which occurs annually. The goal of the campaign is to
accinate 80% of the target population against inﬂuenza, and,
n 2011, it has achieved 84% vaccination coverage.30 The vac-
ination for pneumonia was still less frequent (5.8%), and all
atients were also vaccinated for inﬂuenza. These values are
ower than those reported in the literature, ranging from 20.2%
o 43%.25,28 Age over 60 years was a factor that inﬂuenced
accination against inﬂuenza and pneumonia, as also was
bserved in other countries,24,28,31 which is possibly explained
y the extensive media coverage of the National Campaign for
lderly Vaccination.
The vaccine against H1N1 inﬂuenza was the most used
y our patients (61.7%), thanks to a national campaign due
o the pandemic in 2009, which included immunosuppressed
atients. This demonstrates that when patients are better tar-
eted, the vaccination coverage can be more  effective. In a
razilian study of RA patients, the vaccine was well tolerated
nd safe, despite a lower seroconversion.32
Infections in patients with RA have gained greater con-
ern with the emergence of the so-called biological agents,
ncluding inhibitors of tumor necrosis factor-alpha (anti-
NF), rituximab, tocilizumab, and abatacept. These drugs
re commonly used in combination with traditional DMARDs,
urther increasing the immunosuppressive effect of these
rugs.10 The use of rituximab may compromise the response
f some immunizations, such as pneumococcal and ﬂu vac-
ines, due to its mechanism of action; thus, the administration
f these vaccines is recommended before beginning that
edication.8,33
Feutchtenbeger et al. noted a higher rate of vaccination
gainst inﬂuenza and Streptococcus pneumoniae in patients who
ere on anti-TNF or rituximab.25 However, no difference was
bserved in relation to medical advice or not vaccination in
atients who were using biologicals. In patients vaccinated
gainst hepatitis B, leﬂunomide was less used – an apparently
ortuitous ﬁnding. We  did not observe an increased presence
f liver disease in these patients.
Patients vaccinated for viral hepatitis B and MMR  were
ounger. This is because the target population for MMR  vac-
ine are women 20-49 years and men  20-39 years. Likewise, the
ational immunization schedule recommends hepatitis B vac-
ination for adults belonging to risk groups such as pregnant
omen, health professionals, workers of different areas, and
isky sexual groups. This population is also often quoted as
eing younger.21 4;5 4(5):349–355 353
The low frequency of use of varicella and antimeningo-
coccal vaccines is justiﬁed by the non-routine offer of these
vaccines by the public health system in Brazil. There was no
registry of use of HPV vaccine, which is also currently offered
by private medical services.
Vaccination with live attenuated components (MMR,  vari-
cella and yellow fever) was very frequent and inadvertently
made. The use of live attenuated vaccines should be avoided
when possible, but these products may be generally used
in moderately immunosuppressed patients, with each case
being individually evaluated.8
With respect to anti-yellow fever vaccine, Mota et al.
observed in another study conducted in our department 52
patients with RA who had received this vaccine. Of these,
12.8% had only mild adverse effects. There were no seri-
ous reactions or deaths.12 Considering that yellow fever is
endemic in a great part of Brazil, the vaccination against this
disease is indicated for the resident population in an exten-
sive part of the national territory (in addition to travellers to
these regions). However, the current recommendation is that
patients undergoing immunosuppressive therapy should not
be vaccinated against this disease.13
The study showed that a high percentage of patients in our
early RA cohort, living in an endemic area for yellow fever, are
vaccinated regardless of medical advice.
It is essential for rheumatologists from endemic areas
being able to instruct the patients about areas with recom-
mendation of the vaccine, epidemics and outbreaks, as well
as evaluating the individual risk of infection and degree of
immunosuppression for each patient.
Although this is the ﬁrst study evaluating the vaccination
status of patients with early RA, it has some limitations. The
study did not evaluate the vaccination card of all patients,
because the card had been lost by a few individuals. In these
cases, the record of the vaccines may not have been done
reliably, due to the patients’ memory  bias. The reasons by
which some patients missed out immunization were also not
evaluated – such as allergies and previous vaccine reactions,
even when they were briefed by the doctor. The knowledge of
these reasons would help us to optimize the patients’ vac-
cination coverage. Another limitation was that we  did not
assess seroconversion, seroprotection and adverse reactions
from vaccines.
After this study, our service is trying to offer guidance
on the appropriate use of vaccines, and routinely assess the
immunization status of patients with early RA. This has been
done in form of a checklist, especially prior to treatment with
DMDs. Ideally, this assessment should be made not only by
rheumatologists in secondary/tertiary care health services,
but also at the primary level of health care, by non-specialist
doctors and nurses.
In conclusion, patients in our Brasilia cohort of early
RA were infrequently briefed by their doctors regarding the
use of vaccines; in our view, this can reﬂect the reality of
most services in Brazil. There was a high frequency of inad-
vertent vaccination with live attenuated virus, with all the
risks associated with this practice. The vaccination cover-
age with killed virus, especially inﬂuenza and pneumonia
(which are the most recommended) ones, was suboptimal;
such vaccination was not the result of the orientation of the
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rheumatologist, but to the patient’s spontaneous demand for
the vaccine.
Thus, both doctors and patients should be better informed
as to the necessity of vaccination, given that infections are an
important cause of morbidity and mortality in patients with
RA. In this scenario, the dissemination and implementation
of the recommendations contained in the Brazilian Society
of Rheumatology Consensus 2012 on Vaccination in Patients
with Rheumatoid Arthritis may be of great importance for
improving the clinical practice of rheumatologists.16
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